ETC

Recommend
Index
  • Adacel

    Adacel

    Ingredient

    noninfectious tetanus, diphtheria, and pertussis proteins, aluminum
    phosphate, 2-phenoxyethanol, and residual amounts of formaldehyde and glutaraldehyde.

    Content
    Indication

    active booster immunization against
    tetanus, diphtheria and pertussis. Adacel is approved for use in persons 10
    through 64 years of age.

  • Aggrastat Inj.

    Aggrastat Inj.

    Ingredient

    Tirofiban Hydrochloride Hydrate 

    Content

    14.05mg/50ml (12.5mg/50ml as tirofiban)

    Indication

    Co-administration with heparin in the patients who are:
    – target patients in the treatment of acute coronary syndrome (ACS)
    – patients with percutaneous transluminal coronary angioplasty (PTCA) or atherectomy

    It has been shown to reduce the incidence of death, myocardial infarction, or combined endpoints of refractory ischemia/recardiac procedures.

  • Allegra Tab. 180mg

    Allegra Tab. 180mg

    Ingredient

    Fexofenadine Hydrochloride

    Content

    180mg

    Indication

    Relief of symptoms associated with allergic skin disease (chronic idiopathic urticaria).

  • Allegra Tab. 30mg

    Allegra Tab. 30mg

    Ingredient

    Fexofenadine Hydrochloride

    Content

    30mg

    Indication

    Relief of symptoms associated with seasonal allergic rhinitis and allergic skin diseases (chronic idiopathic urticaria)

  • Allegra-D

    Allegra-D

    Ingredient

    Fexofenadine Hydrochloride 60mg
    Pseudoephedrine Hydrochloride 120mg

    Content

    Fexofenadine Hydrochloride 60mg
    Pseudoephedrine Hydrochloride 120mg

    Indication

    1. Relief of the following symptoms due to seasonal allergic rhinitis: sneezing, runny nose, itchy nose, mouth, throat, itching eyes, lacrimation, hyperemia, nasal congestion

    2. Use this drug when both the antihistamine effect of fexofenadine hydrochloride and the decongestant effect of pseudoephedrine hydrochloride are required.

  • Amaryl M Tab.

    Amaryl M Tab.

    Ingredient

    Glimepiride/Metformin Hydrochloride

    Content

    1/250mg, 1/500mg, 2/500mg

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of glimepiride and metformin.

  • Amaryl Mex SR Tab.

    Amaryl Mex SR Tab.

    Ingredient

    Glimepiride/Metformin Hydrochloride

    Content

    2mg/500mg

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of glimepiride and metformin.

  • Amaryl Tab.

    Amaryl Tab.

    Ingredient

    Glimepiride

    Content

    1mg, 2mg, 4mg

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes.
    – Monotherapy
    – Combination therapy

  • Arixtra Inj.

    Arixtra Inj.

    Ingredient

    Fondaparinux Sodium

    Content

    2.5mg/0.5ml (pre-filled syringe)

    Indication

    1) Prophylaxis of venous thromboembolism in patients undergoing major orthopedic surgery of the lower limb, such as hip fracture surgery, knee surgery, or hip replacement surgery
    2) Prophylaxis of venous thromboembolism in patients underwent abdominal surgery, such as abdominal cancer surgery who are deemed to have a high risk of thromboembolic complications
    3) Prophylaxis of venous thromboembolism in patients with limited mobility due to acute diseases such as heart failure (NYHA class Ⅲ or Ⅳ), acute respiratory disease, acute infection or inflammatory disease and medical patients who are deemed to have a high risk of venous thromboembolism
    4) Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients who are not covered by emergency invasive management (Percutaneous Coronary Intervention(PCI) within 120 minutes)
    5) Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are being treated with thrombolytic agents or initially not receiving other forms of reperfusion therapy

  • AVAXIM 160U ADULT INJ.

    AVAXIM 160U ADULT INJ.

    Ingredient

    Hepatitis A virus, GBM strain (inactivated)1, 2……160 EU

    Content
    Indication

    active immunisation against hepatitis A infection in adults and
    children 2 years and over

TOP